Literature DB >> 15016952

Assessment of contraceptive vaccines based on recombinant mouse sperm protein PH20.

Christopher M Hardy1, Gavin Clydesdale, Karen J Mobbs, Jenny Pekin, Megan L Lloyd, Clive Sweet, Geoffrey R Shellam, Malcolm A Lawson.   

Abstract

Mouse PH20 (mPH20), the mouse homologue to guinea pig hyaluronidase protein PH20 (gpPH20), was used to produce contraceptive vaccines that target both sexes of mice. Previously, immunization with a female gamete antigen (the zona pellucida subunit 3 protein) delivered in a recombinant murine cytomegalovirus (MCMV), or as a purified recombinant protein, has been shown to induce infertility in female mice. There is evidence, however, that sperm protein antigens could provide broader contraceptive coverage by affecting both males and females, and the most promising has been gpPH20 when tested in a guinea pig model. Mice were therefore either inoculated with a recombinant MCMV expressing mPH20 or immunized directly with purified recombinant mPH20 protein fused to maltose-binding protein. Mice treated with either vaccine formulation developed serum antibodies that cross-reacted to a protein band of 55 kDa corresponding to mPH20 in Western blots of mouse sperm. However, there was no significant reduction in the fertility of males or females compared with control animals with either formulation. We conclude from our data that recombinant mPH20 is not a useful antigen for inclusion in immunocontraceptive vaccines that target mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016952     DOI: 10.1530/rep.1.00016

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  7 in total

1.  Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception.

Authors:  Alec J Redwood; Martin Messerle; Nicole L Harvey; Christopher M Hardy; Ulrich H Koszinowski; Malcolm A Lawson; Geoffrey R Shellam
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration.

Authors:  Marie A Printz; Barry J Sugarman; Rudolph D Paladini; Michael C Jorge; Yan Wang; David W Kang; Daniel C Maneval; Michael J LaBarre
Journal:  AAPS J       Date:  2022-10-20       Impact factor: 3.603

Review 3.  Hyalurondiase: both a tumor promoter and suppressor.

Authors:  Vinata B Lokeshwar; Marie G Selzer
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

Review 4.  Hyaluronan and hyaluronidase in genitourinary tumors.

Authors:  Melanie A Simpson; Vinata B Lokeshwar
Journal:  Front Biosci       Date:  2008-05-01

5.  Hyaluronan anchored to activated CD44 on central nervous system vascular endothelial cells promotes lymphocyte extravasation in experimental autoimmune encephalomyelitis.

Authors:  Clayton W Winkler; Scott C Foster; Steven G Matsumoto; Marnie A Preston; Rubing Xing; Bruce F Bebo; Fatima Banine; Michelle A Berny-Lang; Asako Itakura; Owen J T McCarty; Larry S Sherman
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

Review 6.  Antisperm antibodies and conception.

Authors:  L W Chamley; G N Clarke
Journal:  Semin Immunopathol       Date:  2007-06       Impact factor: 11.759

7.  Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Authors:  Sanna Rosengren; Samuel S Dychter; Marie A Printz; Lei Huang; Richard I Schiff; Hans-Peter Schwarz; John K McVey; Fred H Drake; Dan C Maneval; Don A Kennard; Gregory I Frost; Barry J Sugarman; Douglas B Muchmore
Journal:  AAPS J       Date:  2015-05-13       Impact factor: 4.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.